5,6,7-Trihydroxy-2-(4-phenylphenyl)chromen-4-one | 859505-70-7

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 黄酮类化合物
• 英文名称: 5,6,7-Trihydroxy-2-(4-phenylphenyl)chromen-4-one
• CAS: 859505-70-7
• 化学式: C₂₁H₁₄O₅
• 分子量: 346.339
• InChiKey: BDMMUACGTYIFDP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  26
• 可旋转键数：
  2
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  87
• 氢给体数：
  3
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  4-苯基肉桂酰氯 在 三氟化硼乙醚 、 氢溴酸 、 碘 、 溶剂黄146 作用下， 以 二氯甲烷 、 二甲基亚砜 为溶剂， 反应 51.17h， 生成 5,6,7-Trihydroxy-2-(4-phenylphenyl)chromen-4-one
  参考文献：
  名称：

  Synthesis and Anti-influenza Activities of Novel Baicalein Analogs

  摘要：

  一系列新型黄酮衍生物是基于对传统中药黄芩（Scutellaria baicalensis GEORGI）活性成分的修饰合成的，并进行了抗流感活性筛选。合成的大黄素（黄酮）类似物，特别是B环上带有溴原子取代的类似物，对H1N1达菲耐药（H1N1 TR）病毒的活性远超奥司他韦或利巴韦林，并且通常具有更优越的选择性。最有希望的化合物是5b、5c、6b和6c，它们的50%有效浓度（EC50）都在4.0–4.5 µM左右，选择指数（SI=50%细胞毒性浓度（CC50）/EC50）>70。对于季节性H3N2流感病毒感染，5a和5b的SI均大于17.3，优于利巴韦林。这些具有非天然溴取代B环和A环上适当羟基位置的黄酮类化合物可能在决定抗H1N1达菲耐药流感病毒的活性和选择性方面起关键作用。

  DOI：

  10.1248/cpb.c13-00897

文献信息

• Methods of synthesizing flavonoids and chalcones
  申请人：Unitech Pharmaceuticals, Inc.

  公开号：US20040242907A1

  公开（公告）日：2004-12-02

  Simple and efficient total syntheses of flavonoids including baicalein, oroxylin A and wogonin are described herein. Simultaneous syntheses of oroxylin A and wogonin are also described.

  以下是您请求的翻译结果： 简单高效地全合成包括黄芩素、木犀草素A和汉黄芩素在内的黄酮类化合物。同时，还描述了木犀草素A和汉黄芩素的同步合成。
• Novel Baicalein-Derived Inhibitors of Plasmodium falciparum
  作者：Chandra Sekhar Gudla、Vignesh Selvam、Siva Shanmugam Selvaraj、Renu Tripathi、Prince Joshi、Salique Hassan Shaham、Mayas Singh、Radha Krishan Shandil、Saman Habib、Shridhar Narayanan

  DOI：10.3390/pathogens12101242

  日期：——

  Malaria, a life-threatening mosquito-borne disease caused by Plasmodium parasites, continues to pose a significant global health burden. Despite notable progress in combating the disease in recent years, malaria remains prevalent in many regions, particularly in Southeast Asia and most of sub-Saharan Africa, where it claims hundreds of thousands of lives annually. Flavonoids, such as the baicalein class of compounds, are known to have antimalarial properties. In this study, we rationally designed and synthesized a series of baicalein derivatives and identified a lead compound, FNDR-10132, that displayed potent in vitro antimalarial activity against Plasmodium falciparum (P. falciparum), both chloroquine-sensitive (60 nM) and chloroquine-resistant (177 nM) parasites. FNDR-10132 was evaluated for its antimalarial activity in vivo against the chloroquine-resistant strain Plasmodium yoelii N67 in Swiss mice. The oral administration of 100 mg/kg of FNDR-10132 showed 44% parasite suppression on day 4, with a mean survival time of 13.5 ± 2.3 days vs. 8.4 ± 2.3 days of control. Also, FNDR-10132 displayed equivalent activity against the resistant strains of P. falciparum in the 200–300 nM range. This study offers a novel series of antimalarial compounds that could be developed into potent drugs against chloroquine-resistant malarial parasites through further chemistry and DMPK optimization.

  疟疾是一种由疟原虫引起的威胁生命的蚊媒疾病，继续对全球健康造成重大负担。尽管近年来在防治疟疾方面取得了显著进展，但疟疾仍在许多地区流行，尤其是在东南亚和撒哈拉以南非洲的大部分地区，每年有数十万人因此而丧生。众所周知，黄酮类化合物（如黄芩素类）具有抗疟特性。在这项研究中，我们合理地设计和合成了一系列黄芩苷衍生物，并确定了一种先导化合物 FNDR-10132，该化合物对恶性疟原虫（P. falciparum）、氯喹敏感寄生虫（60 nM）和氯喹抗性寄生虫（177 nM）均显示出强大的体外抗疟活性。FNDR-10132 在瑞士小鼠体内对耐氯喹的yoelii N67 株疟原虫的抗疟活性进行了评估。口服 100 毫克/千克 FNDR-10132 后，第 4 天的寄生虫抑制率为 44%，平均存活时间为 13.5 ± 2.3 天（对照组为 8.4 ± 2.3 天）。此外，FNDR-10132 在 200-300 nM 范围内对恶性疟原虫耐药菌株显示出同等的活性。这项研究提供了一系列新型抗疟化合物，通过进一步的化学和 DMPK 优化，可将其开发成抗耐氯喹疟原虫的强效药物。
• Synthesis and Anti-influenza Activities of Novel Baicalein Analogs
  作者：Shu-Ting Chung、Pei-Yu Chien、Wen-Hsin Huang、Chen-Wen Yao、An-Rong Lee

  DOI：10.1248/cpb.c13-00897

  日期：——

  A series of novel flavones derivatives were synthesized based on modification of the active ingredients of a traditional Chinese medicine Scutellaria baicalensis GEORGI and screened for anti-influenza activity. The synthetic baicalein (flavone) analogs, especially with the B-rings substituted with bromine atoms, were much more potent than oseltamivir or ribavirin against H1N1 Tamiflu-resistant (H1N1 TR) virus and usually with more favorable selectivity. The most promising were 5b, 5c, 6b and 6c, all displaying an 50% effective concentration (EC50) at around 4.0–4.5 µM, and a selective index (SI=50% cytotoxic concentration (CC50)/EC50)>70. For seasonal H3N2-infected influenza virus, both 5a and 5b with SI >17.3 indicated superior to ribavirin. The flavonoids having both not-naturally-occurring bromo-substituted B-rings and appropriate hydroxyls positioning on the A-rings might be critical in determining the activity and selectivity against H1N1-Tamiflu-resistant infected influenza viruses.

  一系列新型黄酮衍生物是基于对传统中药黄芩（Scutellaria baicalensis GEORGI）活性成分的修饰合成的，并进行了抗流感活性筛选。合成的大黄素（黄酮）类似物，特别是B环上带有溴原子取代的类似物，对H1N1达菲耐药（H1N1 TR）病毒的活性远超奥司他韦或利巴韦林，并且通常具有更优越的选择性。最有希望的化合物是5b、5c、6b和6c，它们的50%有效浓度（EC50）都在4.0–4.5 µM左右，选择指数（SI=50%细胞毒性浓度（CC50）/EC50）>70。对于季节性H3N2流感病毒感染，5a和5b的SI均大于17.3，优于利巴韦林。这些具有非天然溴取代B环和A环上适当羟基位置的黄酮类化合物可能在决定抗H1N1达菲耐药流感病毒的活性和选择性方面起关键作用。